Co-formulated agents include: GSNO that is both endogenously ubiquitous and used therapeutically in a variety of preclinical cardiovascular and infectious disease applications; CTLA-4 antagonizing mAbs, which compared to other more recently developed ICB mAbs achieve overall lower rates of patient response clinically as a monotherapy1–7 but offer numerous attributes favorable to abscopal-eliciting locoregional therapies, including lower systemic adverse effects and broadening of the clonal repertoire of antitumor T cells34. Here, CTLA4 is linked to infectious disease.